2025年1月13日 · Our data revealed a statistically significant elevation in sPD-1 and sADO levels in CD38 positive B-NHL patients compared to CD38 negative B-NHL (P-value < 0.01).

Abnormal expression of CD38 is present in approximately two-thirds of FL, though at a lower level compared to more aggressive NHL variants, probably reflecting the lower proliferative burden. Variable levels of expression of CD38 can be detected, however, do not appear to correlate with different histological grades [ 63 ].

cd38在恶性淋巴细胞肿瘤中广泛表达，使其成为肿瘤免疫疗法的热门候选靶点之一。然而，目前靶向cd38免疫治疗非霍奇金淋巴瘤(nhl)患者的临床应用价值较为有限，这可能与cd38异常表达导致肿瘤细胞对cd38单克隆抗体产生耐药有关。

2024年11月5日 · Adoption of conventional 1-step radioimmunotherapy for NHL has nevertheless been limited. CD38-SADA PRIT employs a 2-step approach with CD38-SADA, a self-assembling and disassembling bispecific fusion protein with high-binding affinity for the CD38 antigen and select radionuclides chelated to tetraxetan (“DOTA”). CD38-SADA is linked to a ...

2016年12月2日 · CD38 has been reported by several authors as one of the best LAIP marker for the detection of MRD in B-ALL, allowing a good follow-up of the patients because of its stability. Moreover, this study confirms that CD38 could be a valuable therapeutic target in most of B-ALL cases, being expressed in over 95% of the cases.

2018年2月8日 · In murine xenograft models of MM and non-Hodgkin lymphoma (NHL), the CD38-bispecific construct demonstrated excellent blood clearance and tumor targeting. Dosimetry calculations showed a tumor-absorbed dose of 43.8 Gy per millicurie injected dose of 90 Y, with tumor-to-normal organ dose ratios of 7:1 for liver and 15:1 for lung and kidney. In ...

CD38 is expressed in several types of non-Hodgkin lymphoma (NHL) and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti-CD38 antibody approved for the treatment of relapsed/refractory (R/R) multiple myeloma (MM).

2022年9月1日 · CD38 is also an attractive target for immunotherapy in B cell-non-Hodgkin lymphoma (B-NHL) given that B-NHL cells also always express it [98], [104]. When the T-cell line hut78 was transduced with an anti-CD38-CAR, it was strongly cytotoxic against B-NHL cell lines as well as lymphoma cells isolated from patients [100] .

CD38, highly expressed in B-cell non-Hodgkin lymphoma (B-NHL) cells, is an attractive target in immunotherapy for B-NHL. We retrovirally transduced a T-cell line, Hut78, expressing little CD38, with an anti-CD38-CAR.

2020年2月13日 · The present review discusses current knowledge of CD38 expression and its implications in various lymphoid malignancies. Furthermore, it addresses current and future therapeutic perspectives, with a particular emphasis on the significance of CD38 interaction with immune cells of the tumor microenvironment.